

Public Declaration of Interests and Confidentiality Undertaking of Swissmedic Medicines Expert Committee Members

This document is aligned to the 'Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA) Scientific Committee members and experts' of the EMA.

SECTION 1: PERSONAL DETAILS

First Name Christian Philipp

Last Name Kamm

Organisation / Company LUKS Spitalbetriebe AG

Country of Organisation /
Company Switzerland

Committee

I do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below.

Please specify the interests that you currently have (at the time of completion of the form) or have had within the past 5 years.

SECTION 2: PUBLIC DECLARATION OF INTERESTS**2.1 Employment** No Yes

Please indicate if you are employed / have been employed, either full or part time, either as paid or unpaid employee in pharmaceutical company.

Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

2.2 Consultancy

No Yes

Choose "Yes" if there is any activity in which you provide or have provided advice or services regardless as to whether or not you received a fee for this activity. Please indicate all of them below.

Provision of advice or services to a pharmaceutical company (in a particular field such as the development of a product) regardless of contractual arrangements or any form of remuneration. (Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product)

Involvement in Data Safety Monitoring Committee should be included in this section.

Note: Conference / Seminar attendance is not considered as consultancy but should be indicated under Financial Interests, if subject to a fee / honoraria.

Period	Company	Product	Therapeutic Indication General Role / Area of Activity	Funding
01/2020 - 04/2024	Novartis (individual Consultancies)	Siponimod, Ofantunumab (individual Consultancies)	Multiple sclerosis	
09/2020 - 06/2023	Celgene (individual Consultancy)	Fampyra	Multiple sclerosis	
06/2020 - 03/2024	Eli Lilly (individual Consultancy)	Ozanimod	Multiple sclerosis	
09/2020 - 09/2021	Sanofi (individual Consultancies)	Tecfidera	Multiple sclerosis	
11/2020 - 04/2022	Merck (individual Consultancies)	Aubagio, Tolebrutinib	<i>Migraine /Cluster headache</i>	
11/2020 - 11/2021	Biogen (individual Consultancies)	Cladribine, Evobrutinib	Multiple sclerosis	
02/2021 - 10/2021	Genentech (individual Consultancy)	Cladribine	Multiple sclerosis <i>Multiple sclerosis</i>	
01/2020 - 09/2023	Sanofi Aventis (individual Consultancies)		<i>Neurology</i>	
04/2021	Roche (individual Consultancies)		<i>neurology</i>	

03/2021 - Alexion (individual
04/2021 Consultancies)

Multiple sclerosis

08/2021 - Biogen (individual
01/2022 Consultancies)

Multiple sclerosis

11/2021 - Biogen (individual
04/2022 Consultancy)

MS GO

Multiple sclerosis

04/2022 Novartis (individual
Consultancies)

Tecfidera, Tysabri,
Pledrigy, Vumerity, Fampyra

NMOSD

06/2023 Bristol Myers Squibb
(individual Consultancies)

Tecfidera, Tysabri or
Vumerity

Multiple sclerosis

03/2024 Janssen (individual
Consultancies)

Multiple sclerosis

03/2024 Alira Health (individual
Consultancy)

Multiple sclerosis

06/2023 Horizon Therapeutics
(individual Consultancy)

Multiple sclerosis

03/2024 Roche (individual
Consultancy)

Software as Medical Device

03/2024 Amgen (individual
Consultancy)

NMOSD

03/2024 Roche

NMOSD

03/2024 Amgen

NMOSD

2.3 Strategic Advisory Role

No Yes

Choose "Yes" if you are participating or have participated in a (Scientific) Advisory Board/Steering Committee of a pharmaceutical company (e.g. board membership / directorship), with a right to vote on / influence the outcome of that body.

Participation (with a right to vote on/influence the outputs) in a (Scientific) Advisory Board/Steering Committee with the role of providing advice/expressing opinions on the (future) strategy, direction or development activities of a pharmaceutical company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration. Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

Note: Involvement in Data Safety Monitoring Committees is not included in this category. Such involvement should be recorded under section 2.2 Consultancy. Involvement in clinical research should be listed under section 2.6 Principal Investigator or 2.7 Investigator as appropriate.

2.4 Current Financial Interests

No Yes

Choose "Yes" if you have any financial interests currently held in a pharmaceutical company.

Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/pension. Compensation, fees, honoraria, salaries currently being paid directly to you by a pharmaceutical company, other than payment for expenses incurred with research work or re-imbursment of reasonable expenses incurred in relation to conference/seminar attendance (i.e. accommodation and travel costs).

Current is interpreted at time of completion of this form.

2.5 Patent

No Yes

Choose "Yes" if any patent for a medicinal / competitor product is currently owned by either yourself or your institution and you are a beneficiary.

Current is interpreted at time of completion of this form.

2.6 Principal Investigator

No Yes

Choose "Yes" if there are trials for which you are acting or have acted as Principal Investigator

Principal Investigator with the responsibility for the coordination of investigators at different centres participating in a multicentre trial or the leading investigator of a monocentre trial, or the coordinating (principal) investigator signing the clinical study report. This definition does not include a national coordinating investigator in a multinational trial.

2.7 Investigator

No Yes

Choose "Yes" if there are trials for which you are acting or have acted as Investigator.

Investigator involved in a clinical trial at a specific trial site who can be the responsible lead investigator of the trial at that specific site or a member of the clinical trial team who performs critical trial related procedures and makes important trial related decisions.

Period	Company	Product	Therapeutic Indication <i>General Role / Area of Activity</i>	Funding
05/2018 - 06/2023	Roche	Ocrevus	Multiple Sclerosis	yes
04/2019 - 04/2023	Novartis	Aimovig	Migraine	yes
09/2020 - 12/2024	TEVA	Fremanezumab	Migraine	yes
01/2022 - 12/2024	Novartis	Kesimpta	Multiple Sclerosis	yes
03/2022 - TODAY	Roche	Ocrevus	Multiple Sclerosis	yes
04/2019 - 10/2021	Eli Lilly	Lasmiditan	Migraine	yes
12/2023 - 12/2025	Biogen	Tysabri	Multiple Sclerosis	yes

2.8 Grant / Funding to organisation/institution

No Yes

Choose "Yes" if any grants or other funding is currently received by your institutional unit from a pharmaceutical company and you receive no personal gain; or where your Organisation (e.g. Patient Organisation) receives a grant or other funding from a pharmaceutical company and you (irrespective if you are employed by the Organisation or are a volunteer) receive no personal gain.

Refers to a grant or other funding from a pharmaceutical company, currently being received (as far as the individual is aware) by an institution (please indicate funding to the smallest institutional unit) or an organisation (e.g. patient organisation), irrespective of whether or not the individual is employed or is a volunteer, and the individual receives no personal gain.

<input type="button" value="X"/>	
Name of Pharmaceutical Company	Roche
Subject Matter	Development of a new Virtual Reality (VR) Headset-based dexterity training in multiple sclerosis" Project end 12.2024
Amount of Money (CHF)	50'000
Funding paid into an institutional account with shared power of disposition?	<input type="text" value="yes"/>

<input type="button" value="X"/>	
Name of Pharmaceutical Company	Novartis
Subject Matter	Development of a new Virtual Reality (VR) Headset-based dexterity training in multiple sclerosis" Project end 12.2024
Amount of Money (CHF)	50'000
Funding paid into an institutional account with shared power of disposition?	<input type="text" value="yes"/>

2.9 Any other interests or facts

No Yes

Choose "Yes" if further to the interest declared above you have any other interests or facts that should be made known to Swissmedic, the Swiss Agency of Therapeutic Products and the public.

By choosing "No" you declare on your honour that you do not have any other interests or facts to declare accordingly.

X

Please specify

Consultant doctor, Department of Neurology, University Hospital Basel, University Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB).

- Neurostatus-EDSS Expert: Consultant for reviewing EDSS assessments in studies since 2020
- Member Independent Adjunction committee to assess relapse in studies since 2023
- Member Independent Adjunction committee to assess disease progression in studies since 2025

X

Please specify

Associate Editor, Journal «Multiple Sclerosis and related disorders» (MSARD), section neurorehabilitation, since 2022.

X

Please specify

08.2021: Vortrag „Patientenfälle Aimovig und erste Erfahrungen mit Kesimpta" - Novartis
01.2022: Vortrag "Disease overview, disease burden, patient pathway" - Janssen
11.2023: Vortrag "ECTRIMS 2023 Highlights" - Merck
11.2023: Chair und Vortrag Biogen symposium "Multiple Sclerosis Across the Life Span: Challenges and Opportunities" within the congress "Gemeinsame Jahrestagung" 2023 SNG